nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—migraine—Prednisone—chronic obstructive pulmonary disease	0.761	1	CpDpCtD
Naratriptan—Almotriptan—CYP1A2—chronic obstructive pulmonary disease	0.000997	1	CrCbGaD
Naratriptan—HTR1D—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000535	0.0128	CbGpPWpGaD
Naratriptan—HTR1B—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000524	0.0125	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.00051	0.0122	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	0.000475	0.0114	CbGpPWpGaD
Naratriptan—HTR1D—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.00045	0.0108	CbGpPWpGaD
Naratriptan—HTR1B—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.00044	0.0105	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000429	0.0103	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000399	0.00955	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	0.000372	0.00889	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000355	0.00849	CbGpPWpGaD
Naratriptan—MAOA—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000348	0.00832	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000335	0.00802	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000329	0.00787	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000299	0.00715	CbGpPWpGaD
Naratriptan—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00153	CcSEcCtD
Naratriptan—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.0015	CcSEcCtD
Naratriptan—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000293	0.0015	CcSEcCtD
Naratriptan—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000293	0.0015	CcSEcCtD
Naratriptan—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000291	0.00148	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00029	0.00148	CcSEcCtD
Naratriptan—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00148	CcSEcCtD
Naratriptan—Cough—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00148	CcSEcCtD
Naratriptan—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00147	CcSEcCtD
Naratriptan—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000287	0.00147	CcSEcCtD
Naratriptan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000287	0.00147	CcSEcCtD
Naratriptan—Cough—Montelukast—chronic obstructive pulmonary disease	0.000284	0.00145	CcSEcCtD
Naratriptan—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.000284	0.00145	CcSEcCtD
Naratriptan—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000283	0.00144	CcSEcCtD
Naratriptan—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.00144	CcSEcCtD
Naratriptan—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000283	0.00144	CcSEcCtD
Naratriptan—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000283	0.00144	CcSEcCtD
Naratriptan—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000283	0.00144	CcSEcCtD
Naratriptan—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000283	0.00144	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000282	0.00675	CbGpPWpGaD
Naratriptan—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00144	CcSEcCtD
Naratriptan—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000282	0.00144	CcSEcCtD
Naratriptan—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000282	0.00144	CcSEcCtD
Naratriptan—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00144	CcSEcCtD
Naratriptan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000281	0.00144	CcSEcCtD
Naratriptan—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00144	CcSEcCtD
Naratriptan—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00143	CcSEcCtD
Naratriptan—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00143	CcSEcCtD
Naratriptan—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000277	0.00141	CcSEcCtD
Naratriptan—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000277	0.00141	CcSEcCtD
Naratriptan—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000277	0.00141	CcSEcCtD
Naratriptan—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00141	CcSEcCtD
Naratriptan—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00141	CcSEcCtD
Naratriptan—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000276	0.00141	CcSEcCtD
Naratriptan—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000275	0.00141	CcSEcCtD
Naratriptan—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000274	0.0014	CcSEcCtD
Naratriptan—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.0014	CcSEcCtD
Naratriptan—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000273	0.00139	CcSEcCtD
Naratriptan—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00138	CcSEcCtD
Naratriptan—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00138	CcSEcCtD
Naratriptan—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00138	CcSEcCtD
Naratriptan—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00138	CcSEcCtD
Naratriptan—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00137	CcSEcCtD
Naratriptan—Infection—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00137	CcSEcCtD
Naratriptan—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00136	CcSEcCtD
Naratriptan—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00136	CcSEcCtD
Naratriptan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000267	0.00136	CcSEcCtD
Naratriptan—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000266	0.00136	CcSEcCtD
Naratriptan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000266	0.00136	CcSEcCtD
Naratriptan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000266	0.00136	CcSEcCtD
Naratriptan—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000265	0.00135	CcSEcCtD
Naratriptan—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000265	0.00135	CcSEcCtD
Naratriptan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00135	CcSEcCtD
Naratriptan—Infection—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00135	CcSEcCtD
Naratriptan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000263	0.00134	CcSEcCtD
Naratriptan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000263	0.00134	CcSEcCtD
Naratriptan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000262	0.00134	CcSEcCtD
Naratriptan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00133	CcSEcCtD
Naratriptan—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000261	0.00133	CcSEcCtD
Naratriptan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00026	0.00133	CcSEcCtD
Naratriptan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00026	0.00133	CcSEcCtD
Naratriptan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000258	0.00132	CcSEcCtD
Naratriptan—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00131	CcSEcCtD
Naratriptan—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00131	CcSEcCtD
Naratriptan—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.0013	CcSEcCtD
Naratriptan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00129	CcSEcCtD
Naratriptan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00129	CcSEcCtD
Naratriptan—MAOA—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000253	0.00604	CbGpPWpGaD
Naratriptan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000252	0.00129	CcSEcCtD
Naratriptan—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00129	CcSEcCtD
Naratriptan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00128	CcSEcCtD
Naratriptan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00127	CcSEcCtD
Naratriptan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000247	0.00126	CcSEcCtD
Naratriptan—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000247	0.00126	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00126	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00126	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000245	0.00585	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000244	0.00583	CbGpPWpGaD
Naratriptan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000244	0.00124	CcSEcCtD
Naratriptan—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000242	0.00124	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000242	0.00123	CcSEcCtD
Naratriptan—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.00123	CcSEcCtD
Naratriptan—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000241	0.00123	CcSEcCtD
Naratriptan—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000241	0.00123	CcSEcCtD
Naratriptan—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000241	0.00123	CcSEcCtD
Naratriptan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00122	CcSEcCtD
Naratriptan—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000238	0.00122	CcSEcCtD
Naratriptan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000237	0.00121	CcSEcCtD
Naratriptan—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000236	0.0012	CcSEcCtD
Naratriptan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000235	0.0012	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00119	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00119	CcSEcCtD
Naratriptan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00119	CcSEcCtD
Naratriptan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00119	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00119	CcSEcCtD
Naratriptan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.00118	CcSEcCtD
Naratriptan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.00118	CcSEcCtD
Naratriptan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000232	0.00118	CcSEcCtD
Naratriptan—Pain—Formoterol—chronic obstructive pulmonary disease	0.000232	0.00118	CcSEcCtD
Naratriptan—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.00023	0.00117	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000229	0.00117	CcSEcCtD
Naratriptan—MAOA—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000229	0.00548	CbGpPWpGaD
Naratriptan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000229	0.00117	CcSEcCtD
Naratriptan—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.00116	CcSEcCtD
Naratriptan—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.00116	CcSEcCtD
Naratriptan—Pain—Montelukast—chronic obstructive pulmonary disease	0.000227	0.00116	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000227	0.00543	CbGpPWpGaD
Naratriptan—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000227	0.00116	CcSEcCtD
Naratriptan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000226	0.00116	CcSEcCtD
Naratriptan—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000225	0.00115	CcSEcCtD
Naratriptan—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000225	0.00115	CcSEcCtD
Naratriptan—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000225	0.00115	CcSEcCtD
Naratriptan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00115	CcSEcCtD
Naratriptan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00114	CcSEcCtD
Naratriptan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00114	CcSEcCtD
Naratriptan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00114	CcSEcCtD
Naratriptan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000223	0.00114	CcSEcCtD
Naratriptan—MAOA—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000222	0.00532	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000222	0.00531	CbGpPWpGaD
Naratriptan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000222	0.00113	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000221	0.00528	CbGpPWpGaD
Naratriptan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00113	CcSEcCtD
Naratriptan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00113	CcSEcCtD
Naratriptan—MAOA—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00022	0.00526	CbGpPWpGaD
Naratriptan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00112	CcSEcCtD
Naratriptan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00112	CcSEcCtD
Naratriptan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.0011	CcSEcCtD
Naratriptan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000215	0.0011	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000215	0.00514	CbGpPWpGaD
Naratriptan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.00109	CcSEcCtD
Naratriptan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000214	0.00109	CcSEcCtD
Naratriptan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000213	0.00109	CcSEcCtD
Naratriptan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.00108	CcSEcCtD
Naratriptan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Naratriptan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Naratriptan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Naratriptan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00108	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00021	0.00504	CbGpPWpGaD
Naratriptan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00021	0.00107	CcSEcCtD
Naratriptan—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00021	0.00107	CcSEcCtD
Naratriptan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00107	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000208	0.00498	CbGpPWpGaD
Naratriptan—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.00106	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000206	0.00494	CbGpPWpGaD
Naratriptan—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000206	0.00105	CcSEcCtD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000206	0.00493	CbGpPWpGaD
Naratriptan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.00104	CcSEcCtD
Naratriptan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00103	CcSEcCtD
Naratriptan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.0002	0.00102	CcSEcCtD
Naratriptan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.0002	0.00102	CcSEcCtD
Naratriptan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.00102	CcSEcCtD
Naratriptan—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000199	0.00102	CcSEcCtD
Naratriptan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000195	0.000998	CcSEcCtD
Naratriptan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000194	0.000992	CcSEcCtD
Naratriptan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.000992	CcSEcCtD
Naratriptan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.000979	CcSEcCtD
Naratriptan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000192	0.000979	CcSEcCtD
Naratriptan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00019	0.000972	CcSEcCtD
Naratriptan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.000962	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000188	0.00449	CbGpPWpGaD
Naratriptan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000188	0.000959	CcSEcCtD
Naratriptan—MAOA—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000187	0.00446	CbGpPWpGaD
Naratriptan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000185	0.000946	CcSEcCtD
Naratriptan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000185	0.000946	CcSEcCtD
Naratriptan—MAOA—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000185	0.00442	CbGpPWpGaD
Naratriptan—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.000942	CcSEcCtD
Naratriptan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000184	0.000937	CcSEcCtD
Naratriptan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000182	0.000927	CcSEcCtD
Naratriptan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.000924	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00018	0.00431	CbGpPWpGaD
Naratriptan—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00018	0.000918	CcSEcCtD
Naratriptan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000179	0.000915	CcSEcCtD
Naratriptan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000179	0.000915	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000177	0.00423	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000177	0.00422	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000176	0.00421	CbGpPWpGaD
Naratriptan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000175	0.000896	CcSEcCtD
Naratriptan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.000894	CcSEcCtD
Naratriptan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000172	0.00088	CcSEcCtD
Naratriptan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.00088	CcSEcCtD
Naratriptan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.000872	CcSEcCtD
Naratriptan—Rash—Formoterol—chronic obstructive pulmonary disease	0.000171	0.000872	CcSEcCtD
Naratriptan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.000871	CcSEcCtD
Naratriptan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000171	0.000871	CcSEcCtD
Naratriptan—Headache—Formoterol—chronic obstructive pulmonary disease	0.00017	0.000867	CcSEcCtD
Naratriptan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.000867	CcSEcCtD
Naratriptan—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000169	0.000865	CcSEcCtD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	0.000169	0.00405	CbGpPWpGaD
Naratriptan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000169	0.000864	CcSEcCtD
Naratriptan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000169	0.000864	CcSEcCtD
Naratriptan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000169	0.000861	CcSEcCtD
Naratriptan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000167	0.000854	CcSEcCtD
Naratriptan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000167	0.000853	CcSEcCtD
Naratriptan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000167	0.000852	CcSEcCtD
Naratriptan—Depression—Prednisone—chronic obstructive pulmonary disease	0.000167	0.000851	CcSEcCtD
Naratriptan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000166	0.000849	CcSEcCtD
Naratriptan—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000165	0.000841	CcSEcCtD
Naratriptan—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000164	0.000837	CcSEcCtD
Naratriptan—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000164	0.000837	CcSEcCtD
Naratriptan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00083	CcSEcCtD
Naratriptan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.000828	CcSEcCtD
Naratriptan—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000161	0.000825	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000161	0.00386	CbGpPWpGaD
Naratriptan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.000824	CcSEcCtD
Naratriptan—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000161	0.000823	CcSEcCtD
Naratriptan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.000823	CcSEcCtD
Naratriptan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.000822	CcSEcCtD
Naratriptan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000161	0.000822	CcSEcCtD
Naratriptan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.000818	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000158	0.00378	CbGpPWpGaD
Naratriptan—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000158	0.000807	CcSEcCtD
Naratriptan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000158	0.000805	CcSEcCtD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000157	0.00376	CbGpPWpGaD
Naratriptan—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000795	CcSEcCtD
Naratriptan—MAOA—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000154	0.00369	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000153	0.00366	CbGpPWpGaD
Naratriptan—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00078	CcSEcCtD
Naratriptan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.000776	CcSEcCtD
Naratriptan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.000772	CcSEcCtD
Naratriptan—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000151	0.00077	CcSEcCtD
Naratriptan—HTR1F—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000151	0.0036	CbGpPWpGaD
Naratriptan—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000766	CcSEcCtD
Naratriptan—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000762	CcSEcCtD
Naratriptan—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000749	CcSEcCtD
Naratriptan—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.000749	CcSEcCtD
Naratriptan—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.000737	CcSEcCtD
Naratriptan—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.000724	CcSEcCtD
Naratriptan—MAOA—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000142	0.00339	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000138	0.00331	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000137	0.00329	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000137	0.00327	CbGpPWpGaD
Naratriptan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000695	CcSEcCtD
Naratriptan—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000692	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000135	0.00324	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000135	0.00322	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000135	0.00322	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000134	0.00322	CbGpPWpGaD
Naratriptan—MAOA—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000134	0.00321	CbGpPWpGaD
Naratriptan—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000685	CcSEcCtD
Naratriptan—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000677	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000132	0.00316	CbGpPWpGaD
Naratriptan—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000132	0.000673	CcSEcCtD
Naratriptan—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000667	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.00013	0.00311	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000129	0.00309	CbGpPWpGaD
Naratriptan—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000641	CcSEcCtD
Naratriptan—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000629	CcSEcCtD
Naratriptan—HTR1F—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000121	0.0029	CbGpPWpGaD
Naratriptan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000619	CcSEcCtD
Naratriptan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000617	CcSEcCtD
Naratriptan—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000617	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.00012	0.00288	CbGpPWpGaD
Naratriptan—Agitation—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000613	CcSEcCtD
Naratriptan—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000602	CcSEcCtD
Naratriptan—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000599	CcSEcCtD
Naratriptan—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000117	0.000598	CcSEcCtD
Naratriptan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.000595	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000115	0.00275	CbGpPWpGaD
Naratriptan—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000115	0.000586	CcSEcCtD
Naratriptan—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000578	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000113	0.00271	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000112	0.00269	CbGpPWpGaD
Naratriptan—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000568	CcSEcCtD
Naratriptan—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000568	CcSEcCtD
Naratriptan—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000566	CcSEcCtD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000111	0.00265	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.00011	0.00264	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00011	0.00264	CbGpPWpGaD
Naratriptan—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000561	CcSEcCtD
Naratriptan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000552	CcSEcCtD
Naratriptan—MAOA—Metabolism—APIP—chronic obstructive pulmonary disease	0.000108	0.00258	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	0.000107	0.00257	CbGpPWpGaD
Naratriptan—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000544	CcSEcCtD
Naratriptan—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000544	CcSEcCtD
Naratriptan—HTR1F—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000107	0.00255	CbGpPWpGaD
Naratriptan—Infection—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000541	CcSEcCtD
Naratriptan—HTR1F—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000105	0.00252	CbGpPWpGaD
Naratriptan—Shock—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000536	CcSEcCtD
Naratriptan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000534	CcSEcCtD
Naratriptan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000529	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000103	0.00247	CbGpPWpGaD
Naratriptan—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000526	CcSEcCtD
Naratriptan—HTR1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000102	0.00245	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000101	0.00242	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000101	0.00242	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	9.9e-05	0.00237	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	9.85e-05	0.00236	CbGpPWpGaD
Naratriptan—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.71e-05	0.000496	CcSEcCtD
Naratriptan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.7e-05	0.000495	CcSEcCtD
Naratriptan—HTR1D—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	9.63e-05	0.0023	CbGpPWpGaD
Naratriptan—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	9.57e-05	0.000489	CcSEcCtD
Naratriptan—HTR1B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	9.43e-05	0.00226	CbGpPWpGaD
Naratriptan—Rash—Prednisolone—chronic obstructive pulmonary disease	9.25e-05	0.000472	CcSEcCtD
Naratriptan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.24e-05	0.000472	CcSEcCtD
Naratriptan—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.19e-05	0.000469	CcSEcCtD
Naratriptan—Headache—Prednisolone—chronic obstructive pulmonary disease	9.19e-05	0.000469	CcSEcCtD
Naratriptan—Constipation—Prednisone—chronic obstructive pulmonary disease	9.12e-05	0.000466	CcSEcCtD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	8.84e-05	0.00212	CbGpPWpGaD
Naratriptan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.78e-05	0.000449	CcSEcCtD
Naratriptan—HTR1D—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	8.74e-05	0.00209	CbGpPWpGaD
Naratriptan—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.71e-05	0.000445	CcSEcCtD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	8.66e-05	0.00207	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	8.62e-05	0.00206	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	8.56e-05	0.00205	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	8.54e-05	0.00204	CbGpPWpGaD
Naratriptan—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.47e-05	0.000432	CcSEcCtD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	8.44e-05	0.00202	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	8.44e-05	0.00202	CbGpPWpGaD
Naratriptan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.43e-05	0.00043	CcSEcCtD
Naratriptan—HTR1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.39e-05	0.00201	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	8.37e-05	0.002	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	8.08e-05	0.00193	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	8.03e-05	0.00192	CbGpPWpGaD
Naratriptan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.85e-05	0.000401	CcSEcCtD
Naratriptan—HTR1D—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	7.76e-05	0.00186	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	7.7e-05	0.00184	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	7.7e-05	0.00184	CbGpPWpGaD
Naratriptan—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.65e-05	0.000391	CcSEcCtD
Naratriptan—HTR1F—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	7.61e-05	0.00182	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	7.6e-05	0.00182	CbGpPWpGaD
Naratriptan—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.54e-05	0.000385	CcSEcCtD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	7.54e-05	0.0018	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	7.54e-05	0.0018	CbGpPWpGaD
Naratriptan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.29e-05	0.000372	CcSEcCtD
Naratriptan—HTR1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.18e-05	0.00172	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.15e-05	0.00171	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	7.11e-05	0.0017	CbGpPWpGaD
Naratriptan—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.05e-05	0.00036	CcSEcCtD
Naratriptan—HTR1D—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	7.05e-05	0.00169	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GC—chronic obstructive pulmonary disease	6.96e-05	0.00166	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	6.91e-05	0.00165	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	6.9e-05	0.00165	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	6.87e-05	0.00164	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	6.82e-05	0.00163	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	6.82e-05	0.00163	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	6.8e-05	0.00163	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	6.8e-05	0.00163	CbGpPWpGaD
Naratriptan—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.78e-05	0.000346	CcSEcCtD
Naratriptan—HTR1D—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	6.73e-05	0.00161	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	6.73e-05	0.00161	CbGpPWpGaD
Naratriptan—Rash—Prednisone—chronic obstructive pulmonary disease	6.72e-05	0.000343	CcSEcCtD
Naratriptan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000343	CcSEcCtD
Naratriptan—Headache—Prednisone—chronic obstructive pulmonary disease	6.68e-05	0.000341	CcSEcCtD
Naratriptan—HTR1B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	6.67e-05	0.0016	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	6.6e-05	0.00158	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	6.59e-05	0.00158	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.52e-05	0.00156	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.51e-05	0.00156	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	6.51e-05	0.00156	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.47e-05	0.00155	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	6.43e-05	0.00154	CbGpPWpGaD
Naratriptan—Nausea—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.000323	CcSEcCtD
Naratriptan—HTR1F—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	6.18e-05	0.00148	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	5.95e-05	0.00142	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	5.83e-05	0.00139	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.79e-05	0.00138	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	5.78e-05	0.00138	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.74e-05	0.00137	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.46e-05	0.00131	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	5.4e-05	0.00129	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	5.35e-05	0.00128	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.26e-05	0.00126	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.16e-05	0.00124	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	5.13e-05	0.00123	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.08e-05	0.00122	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	5.06e-05	0.00121	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.02e-05	0.0012	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	4.95e-05	0.00118	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.87e-05	0.00116	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.77e-05	0.00114	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.76e-05	0.00114	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.7e-05	0.00112	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.43e-05	0.00106	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.42e-05	0.00106	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.35e-05	0.00104	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	4.33e-05	0.00104	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	4.26e-05	0.00102	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.16e-05	0.000996	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.16e-05	0.000995	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.08e-05	0.000977	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.08e-05	0.000975	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.08e-05	0.000975	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	4.07e-05	0.000975	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4e-05	0.000956	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.95e-05	0.000945	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.87e-05	0.000925	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.85e-05	0.000922	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.81e-05	0.000911	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.8e-05	0.000909	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GCLC—chronic obstructive pulmonary disease	3.76e-05	0.000899	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.73e-05	0.000892	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.68e-05	0.00088	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.65e-05	0.000873	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.63e-05	0.000869	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.46e-05	0.000827	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CTGF—chronic obstructive pulmonary disease	3.43e-05	0.00082	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	3.38e-05	0.00081	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.34e-05	0.000799	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.32e-05	0.000794	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.3e-05	0.000789	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.25e-05	0.000776	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.19e-05	0.000764	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.16e-05	0.000756	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.11e-05	0.000743	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.1e-05	0.000742	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.04e-05	0.000728	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.98e-05	0.000713	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.97e-05	0.00071	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.95e-05	0.000705	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.84e-05	0.000679	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.83e-05	0.000677	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.77e-05	0.000663	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.63e-05	0.00063	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.61e-05	0.000625	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.6e-05	0.000622	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.58e-05	0.000617	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.56e-05	0.000612	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.44e-05	0.000584	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.42e-05	0.000579	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.35e-05	0.000563	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.33e-05	0.000558	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.33e-05	0.000557	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2.3e-05	0.000551	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.3e-05	0.000549	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.29e-05	0.000547	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.27e-05	0.000543	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.22e-05	0.000532	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.14e-05	0.000511	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.12e-05	0.000508	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.11e-05	0.000505	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.09e-05	0.0005	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.08e-05	0.000497	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.04e-05	0.000488	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2e-05	0.000478	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.97e-05	0.000472	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.95e-05	0.000466	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.9e-05	0.000454	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.88e-05	0.000449	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.86e-05	0.000445	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.78e-05	0.000427	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.75e-05	0.00042	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.74e-05	0.000416	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.6e-05	0.000383	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.59e-05	0.000381	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.58e-05	0.000379	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.56e-05	0.000373	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—chronic obstructive pulmonary disease	1.56e-05	0.000373	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.53e-05	0.000366	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.52e-05	0.000364	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—NOS3—chronic obstructive pulmonary disease	1.49e-05	0.000357	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.49e-05	0.000356	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.47e-05	0.000352	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.46e-05	0.000349	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.44e-05	0.000345	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.42e-05	0.00034	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.42e-05	0.000339	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.39e-05	0.000333	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.26e-05	0.000302	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.24e-05	0.000295	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.21e-05	0.00029	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.2e-05	0.000287	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.17e-05	0.000281	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.16e-05	0.000279	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.14e-05	0.000273	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.12e-05	0.000267	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.11e-05	0.000266	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.11e-05	0.000265	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.06e-05	0.000254	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.02e-05	0.000245	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.41e-06	0.000225	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.4e-06	0.000225	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.22e-06	0.000221	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.21e-06	0.00022	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	9.03e-06	0.000216	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.95e-06	0.000214	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.51e-06	0.000204	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.74e-06	0.000185	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.64e-06	0.000183	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.58e-06	0.000181	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	7.09e-06	0.00017	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.01e-06	0.000168	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.94e-06	0.000166	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.88e-06	0.000165	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.77e-06	0.000138	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.29e-06	0.000126	CbGpPWpGaD
